A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

May 27, 2026 updated by: GlaxoSmithKline

A Phase 3a, Observer-blind, Randomized, Controlled Study to Demonstrate Lot-to-lot Consistency and Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, Administered as a First Dose to Healthy Children 12 to 15 Months of Age

The purpose of this study is to assess the consistency of immune response to three different lots of GSK's investigational varicella vaccine (VNS Vaccine), and to compare the safety and immune response of VNS vaccine to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted in healthy children aged 12 to 15 months, who have neither contracted varicella nor received a varicella vaccination.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1840

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Belgium
      • Brussels, Belgium, 1200
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Xavier STEPHENNE
      • Ghent, Belgium, 9000
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Levi Hoste
      • Gozée, Belgium, 6534
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Marc De Meulemeester
      • Leuven, Belgium, 3000
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • François Vermeulen
      • Liège, Belgium, 4000
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Annabelle Lefevre
  • Colombia
      • Cali, Colombia, 760042
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Viviana Marquez
      • Medellín, Colombia, 050021
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Maria Carolina Ortega Maffla
  • Czechia
      • Jindřichův Hradec, Czechia, 377 01
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Daniela Verdanova
      • Jindřichův Hradec, Czechia, 37701
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Daniel Drazan
      • Jinočany, Czechia, 530 12
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jirina Dvorakova
      • Ostrava, Czechia, 708 00
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • David Zeman
      • Prague, Czechia, 160 00
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Renata Adamovska
  • Dominican Republic
      • Santo Domingo, Dominican Republic, 10201
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Sonia Mazara
      • Santo Domingo, Dominican Republic, 10205
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Sorivel Sosa Hilario
      • Santo Domingo Oeste, Dominican Republic, 11114
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Dania Torres
  • Estonia
      • Paide, Estonia, 72713
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ingrid Alt
      • Tartu, Estonia, 50106
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Airi Poder
  • Mexico
      • Acapulco, Mexico, 39670
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ilya Angelica Rochin-Kobachi
      • Hidalgo, Mexico, 42000
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Joselito Hernandez Pichardo
        • Contact:
        • Contact:
      • Mexico City, Mexico, 6750
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ana Estela Gamiño Arroyo
      • Mexico City, Mexico
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Miguel Angel Rodriguez-Weber
      • Veracruz, Mexico, 91900
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Francisco Salazar Martinez
  • Poland
      • Bydgoszcz, Poland, 85-048
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Piotr Korbal
        • Contact:
        • Contact:
      • Częstochowa, Poland, 42-217
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Elzbieta Janusik
      • Krakow, Poland, 30-363
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Agnieszka Swiat
      • Siemianowice Śląskie, Poland, 41103
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Barbara Pajek
        • Contact:
        • Contact:
      • Torun, Poland, 87-100
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Elzbieta Kopińska
        • Contact:
        • Contact:
  • Puerto Rico
      • Caguas, Puerto Rico, 00725
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Fernando Ysern-Borras
      • Ponce, Puerto Rico, 00716
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Elizabeth Barranco Santana
      • San Juan, Puerto Rico, 00918
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Carmen Deseda
        • Contact:
        • Contact:
      • San Juan, Puerto Rico, 907
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yareri Soto Mendoza
  • Thailand
      • Bangkok, Thailand, 10700
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Orasri Wittawatmongkol
      • Rajathevee, Thailand, 10400
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Veerachai Watanaveeradej
  • United Arab Emirates
      • Abu Dhabi, United Arab Emirates
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Majed Abulhassan
      • Al Ain City, United Arab Emirates
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ghassan Ghatash
  • United States
    • Alabama
      • Mobile, Alabama, United States, 36608
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Paul Matherne
    • Arkansas
      • Hot Springs, Arkansas, United States, 71913
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jon Robert
      • Sherwood, Arkansas, United States, 72120
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Kimberly Clinton
    • California
      • Canoga Park, California, United States, 91304
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • James Saunders
      • Covina, California, United States, 91723
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Holly Lim
        • Contact:
        • Contact:
      • Fullerton, California, United States, 92835
        • Withdrawn
        • GSK Investigational Site
      • Long Beach, California, United States, 90807
        • Withdrawn
        • GSK Investigational Site
      • Los Angeles, California, United States, 90057
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Peyman Banooni
      • Paramount, California, United States, 90723
        • Withdrawn
        • GSK Investigational Site
      • Sacramento, California, United States, 95823
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Marita Biag
      • Ventura, California, United States, 93003
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Carey Chronis
        • Contact:
        • Contact:
      • Walnut Creek, California, United States, 94598
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Timothy Ryschon
      • Winnetka, California, United States, 91306
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Parisa Arman Khorsandi
    • Florida
      • Miami, Florida, United States, 33184
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Lilia Roque Guerrero
        • Contact:
        • Contact:
      • Miami, Florida, United States, 33176
        • Withdrawn
        • GSK Investigational Site
      • Miami Lakes, Florida, United States, 33014
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ihosvani Barroso
      • Spring Hill, Florida, United States, 34609
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Imad Jandali
      • Tampa, Florida, United States, 33613
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Teena Hughes
        • Contact:
        • Contact:
    • Georgia
      • Covington, Georgia, United States, 70433
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Sherri Casey
        • Contact:
        • Contact:
    • Idaho
      • Ammon, Idaho, United States, 83406
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Joseph Moore
    • Illinois
      • Moline, Illinois, United States, 61265
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Nafees Khan
    • Indiana
      • South Bend, Indiana, United States, 46617
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Alicia Wilson
    • Kansas
      • Topeka, Kansas, United States, 66606
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Randall Schumacher
    • Kentucky
      • Bardstown, Kentucky, United States, 40004
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Daniel Finn
        • Contact:
        • Contact:
      • Louisville, Kentucky, United States, 40202-1822
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Gary Marshall
        • Contact:
        • Contact:
    • Louisiana
      • Haughton, Louisiana, United States, 71037
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Stacey Sparks
        • Contact:
        • Contact:
    • Massachusetts
      • Fall River, Massachusetts, United States, 02721-1735
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Walter Rok
    • Michigan
      • Bingham Farms, Michigan, United States, 48025
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Martin Levinson
    • Missouri
      • Jefferson City, Missouri, United States, 65109
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Alfred Johnson
    • Nebraska
      • Lincoln, Nebraska, United States, 68505
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Theodore Pham
      • Lincoln, Nebraska, United States, 68516
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Alexander Ryan
      • Lincoln, Nebraska, United States, 68510
        • Withdrawn
        • GSK Investigational Site
    • New York
      • The Bronx, New York, United States, 10456
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ruby Hussain
    • North Carolina
      • Charlotte, North Carolina, United States, 28203
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Christine Turley
      • Monroe, North Carolina, United States, 28112
        • Withdrawn
        • GSK Investigational Site
    • Ohio
      • Cleveland, Ohio, United States, 44121
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Shelly Senders
        • Contact:
        • Contact:
      • Dayton, Ohio, United States, 45424
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Steve Choi
    • Oklahoma
      • Chickasha, Oklahoma, United States, 73018
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ahmad Musa
      • Tulsa, Oklahoma, United States, 74137
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Erin Latimer
    • Oregon
      • Gresham, Oregon, United States, 97030
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Frank Calcagno
        • Contact:
        • Contact:
    • South Carolina
      • Charleston, South Carolina, United States, 29414
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Robert Clifford
        • Contact:
        • Contact:
      • Charleston, South Carolina, United States, 29407
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • John Traynham
      • Greenville, South Carolina, United States, 29607
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Scott Dobson
      • Simpsonville, South Carolina, United States, 29681
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Stephen Jones
    • Texas
      • Beaumont, Texas, United States, 77701
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Derick Young
      • Burleson, Texas, United States, 76028
        • Withdrawn
        • GSK Investigational Site
      • Corpus Christi, Texas, United States, 78404
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Wieslaw Jakubowski
      • Dallas, Texas, United States, 75230-2571
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Benjamin Marcum
      • Dallas, Texas, United States, 75251
        • Withdrawn
        • GSK Investigational Site
      • Houston, Texas, United States, 77030
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Gloria Heresi
      • Houston, Texas, United States, 77087
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Martin Yudovich
        • Contact:
        • Contact:
      • McAllen, Texas, United States, 78504
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Ashley Bose
        • Contact:
        • Contact:
      • Mesquite, Texas, United States, 75149
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Salma Saiger
    • Utah
      • Layton, Utah, United States, 84041
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Brent Eberhard
        • Contact:
        • Contact:
      • Layton, Utah, United States, 84041
        • Completed
        • GSK Investigational Site
      • Murray, Utah, United States, 84107
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jake Jones
      • Pleasant View, Utah, United States, 84404
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jason Church
      • South Jordan, Utah, United States, 84095
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Kathy Garcia
      • West Jordan, Utah, United States, 84088
        • Withdrawn
        • GSK Investigational Site
    • Virginia
      • Richmond, Virginia, United States, 23226
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Richard Bennett

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Participant's parent(s) Legally acceptable representatives /(LAR[s]), who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiaries, return for follow-up visits).
  • Written or witnessed/thumb printed informed consent obtained from the participant's parent(s)/LAR(s) prior to performance of any study-specific procedure.
  • Healthy participants as established by medical history and clinical examination before entering into the study.
  • A male or female between, and including, 12 to 15 months of age (i.e., from the day of 1-year birthday until the day before 16 months of age) at the time of the administration of study interventions.

  • Only for children in countries where PCV is recommended at 12 to 15 months of age as per national immunization schedule and provided as part of the study interventions:

    • Participant who previously received the primary series of PCV in the first year of life with last dose at least 60 days prior to study entry.

Exclusion Criteria:

  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • Hypersensitivity to latex.
  • Major congenital defects, as assessed by the investigator.
  • Recurrent history of uncontrolled neurological disorders or seizures.
  • History of varicella disease.
  • Active untreated tuberculosis.
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
  • Use of any investigational or non-registered product (drug, vaccine or invasive medical device) other than the study interventions during the period beginning 30 days before the dose of study interventions administration (Day -29 to Day 1), or their planned use during the study period.
  • Planned administration of a vaccine in the period starting 30 days before the dose and ending 43 days after the dose of study interventions administration* (Visit 2) with the exception of inactivated influenza vaccine which may be given at any time during the study and administered at a different location than the study interventions.

Any other age-appropriate vaccine may be given starting at Visit 2 and anytime thereafter.

*If emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is organized by public health authorities outside the routine immunization program, the time period described above can be reduced provided it is used according to the local governmental recommendations and sponsor is notified

  • Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune modifying treatments at any time up to the end of the study.

    • Up to 90 days prior to the study intervention administration:
    • For corticosteroids, this will mean prednisone equivalent >=0.5 mg/kg/day with maximum of 20 mg/day for pediatric participants. Inhaled and topical steroids are allowed.
    • Administration of immunoglobulins and/or any blood products or plasma derivatives.
    • Up to 180 days prior to study interventions administration: long acting immune-modifying drugs including among others immunotherapy (e.g., tumor necrosis factor-inhibitors), monoclonal antibodies (except the ones not interfering with the immune response to the study vaccines, e.g., nirsevimab), antitumoral medication.
  • Previous vaccination against measles, mumps, and rubella.
  • Previous vaccination against hepatitis A virus.
  • Previous vaccination against varicella virus.
  • Only for children in countries where PCV is recommended at 12 to 15 months of age as per national immunization schedule and provided as part of the study interventions, participant who previously received a booster dose of any PCV.
  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device).
  • Child in care.
  • Any study personnel's immediate dependents, family, or household members.

  • Participants with the following high-risk individuals in their household:

    • Immunocompromised individuals.
    • Pregnant women without documented history of varicella.
    • Newborn infants of mothers without documented history of varicella.
    • Newborn infants born less than (<) 28 weeks of gestation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: VNS_Lot 1 Group
Participants receive 1 dose of the investigational VNS vaccine of Lot 1, 1 dose of measles, mumps, and rubella (MMR) vaccine, 1 dose of hepatitis A vaccine (HAV), and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1.
Biological: Investigational varicella vaccine_Lot 1
Investigational varicella vaccine of Lot 1 administered subcutaneously.
Biological: MMR vaccine
MMR vaccine co-administered subcutaneously or intramuscularly.
Biological: Hepatitis A vaccine
Hepatitis A vaccine co-administered intramuscularly.
Biological: PCV (pneumococcal conjugate vaccine) 13
The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Biological: PCV 20
The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Biological: Vaxneuvance
The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Experimental: VNS_Lot 2 Group
Participants receive 1 dose of the investigational VNS vaccine of Lot 2, 1 dose of MMR vaccine, 1 dose of HAV vaccine, and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1.
Biological: MMR vaccine
MMR vaccine co-administered subcutaneously or intramuscularly.
Biological: Hepatitis A vaccine
Hepatitis A vaccine co-administered intramuscularly.
Biological: PCV (pneumococcal conjugate vaccine) 13
The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Biological: PCV 20
The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Biological: Vaxneuvance
The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Biological: Investigational varicella vaccine_Lot 2
Investigational varicella vaccine of Lot 2 administered subcutaneously.
Experimental: VNS_Lot 3 Group
Participants receive 1 dose of the investigational VNS vaccine of Lot 3, 1 dose of MMR vaccine, 1 dose of HAV vaccine, and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1.
Biological: MMR vaccine
MMR vaccine co-administered subcutaneously or intramuscularly.
Biological: Hepatitis A vaccine
Hepatitis A vaccine co-administered intramuscularly.
Biological: PCV (pneumococcal conjugate vaccine) 13
The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Biological: PCV 20
The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Biological: Vaxneuvance
The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Biological: Investigational varicella vaccine_Lot 3
Investigational varicella vaccine of Lot 3 administered subcutaneously.
Active Comparator: VV_Lot 1 Group
Participants receive 1 dose of a marketed varicella vaccine (VV) of Lot 1, 1 dose of MMR vaccine, 1 dose of HAV vaccine, and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1.
Biological: MMR vaccine
MMR vaccine co-administered subcutaneously or intramuscularly.
Biological: Hepatitis A vaccine
Hepatitis A vaccine co-administered intramuscularly.
Biological: PCV (pneumococcal conjugate vaccine) 13
The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Biological: PCV 20
The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Biological: Vaxneuvance
The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Biological: Marketed varicella vaccine_Lot 1
Marketed varicella vaccine of Lot 1 administered subcutaneously.
Active Comparator: VV_Lot 2 Group
Participants receive 1 dose of a marketed VV of Lot 2, 1 dose of MMR vaccine, 1 dose of HAV vaccine, and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1.
Biological: MMR vaccine
MMR vaccine co-administered subcutaneously or intramuscularly.
Biological: Hepatitis A vaccine
Hepatitis A vaccine co-administered intramuscularly.
Biological: PCV (pneumococcal conjugate vaccine) 13
The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Biological: PCV 20
The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Biological: Vaxneuvance
The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Biological: Marketed varicella vaccine_Lot 2
Marketed varicella vaccine of Lot 2 administered subcutaneously.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Percentage of participants with seroresponse to Varicella Zoster Virus (VZV) anti-glycoprotein E (gE) Immunoglobulin (IgG) for the 3 lots of VNS vaccine groups
Time Frame: At Day 43
Seroresponse is defined as post-vaccination (Day 43) anti-VZV gE IgG antibody concentration greater than or equal to (>=) 300 milli-international units per milliliter (mIU/mL) among participants who were seronegative [(antibody concentration less than (<) LLOQ (Lower limit of quantification)] before vaccination. A seronegative participant is a participant whose antibody concentration is below the LLOQ of the assay. A seropositive participant is a participant whose antibody concentration is greater than or equal to the LLOQ of the assay.
At Day 43
Geometric Mean Concentration (GMC) of anti-VZV gE IgG for the 3 lots of VNS vaccine groups
Time Frame: At Day 43
Concentrations of anti-VZV gE IgG presented as GMCs and expressed in mIU/mL for each group.
At Day 43
Percentage of participants with seroresponse to anti-VZV gE IgG for the 3 pooled lots of VNS vaccine groups compared with the 2 pooled lots of VV groups
Time Frame: At Day 43
Seroresponse is defined as post-vaccination (Day 43) anti-VZV gE IgG concentration >= 300 mIU/mL among participants who were seronegative (antibody concentration < LLOQ) before vaccination. A seronegative participant is a participant whose antibody concentration is below the LLOQ of the assay. A seropositive participant is a participant whose antibody concentration is greater than or equal to the LLOQ of the assay.
At Day 43
GMCs of anti-VZV gE IgG for the 3 pooled lots of VNS vaccine groups compared with the 2 pooled lots of VV groups
Time Frame: At Day 43
Concentrations of anti-VZV gE IgG are presented as GMCs and expressed in mIU/mL for each group.
At Day 43

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Percentage of participants reporting each solicited systemic event
Time Frame: Day 1 (post-dose) to Day 15
Solicited systemic events include drowsiness, loss of appetite and irritability.
Day 1 (post-dose) to Day 15
Percentage of participants reporting medically attended AEs (MAAE)
Time Frame: Day 1 (post-dose) to Day 181 (study end)
A MAAE is an AE for which the participant received medical attention including any symptom or illness requiring hospitalization, or an emergency room visit, or visit to/by a healthcare professional.
Day 1 (post-dose) to Day 181 (study end)
Percentage of participants reporting serious adverse events (SAEs)
Time Frame: Day 1 (post-dose) to Day 181 (study end)
A SAE is an AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or other situations that are considered serious per medical or scientific judgment.
Day 1 (post-dose) to Day 181 (study end)
Anti-measles antibodies GMCs for the 3 pooled lots of VNS vaccine groups compared with the 2 pooled lots of VV groups
Time Frame: At Day 43
At Day 43
Anti-mumps antibodies GMCs for the 3 pooled lots of VNS vaccine groups compared with the 2 pooled lots of VV groups
Time Frame: At Day 43
At Day 43
Anti-rubella antibodies GMCs for the 3 pooled lots of VNS vaccine groups compared with the 2 pooled lots of VV groups
Time Frame: At Day 43
At Day 43
Percentage of participants with seroresponse to anti-measles for the 3 pooled lots of VNS vaccine groups compared with the 2 pooled lots of VV groups
Time Frame: At Day 43

Seroresponse is defined as post-vaccination (Day 43) anti-measles antibody concentration >= cut-off value among participants who were seronegative (antibody concentration < cut-off value) before vaccination.

The assay cut-off values for anti-measles will be defined by the laboratory before the analysis.
At Day 43
Percentage of participants with seroresponse to anti-mumps for the 3 pooled lots of VNS vaccine groups compared with the 2 pooled lots of VV groups
Time Frame: At Day 43

Seroresponse is defined as post-vaccination (Day 43) anti-mumps antibody concentration >= cut-off value among participants who were seronegative (antibody concentration < cut-off value) before vaccination.

The assay cut-off values for anti-mumps will be defined by the laboratory before the analysis.
At Day 43
Percentage of participants with seroresponse to anti-rubella for the 3 pooled lots of VNS vaccine groups compared with the 2 pooled lots of VV groups
Time Frame: At Day 43

Seroresponse is defined as post-vaccination (Day 43) anti-rubella antibody concentration >= cut-off value among participants who were seronegative (antibody concentration < cut-off value) before vaccination.

The assay cut-off values for anti-rubella will be defined by the laboratory before the analysis.
At Day 43
Anti-Hepatitis A antibodies GMCs for the 3 pooled lots of VNS vaccine groups compared with the 2 pooled lots of VV groups in Hepatitis A virus (HAV) subset
Time Frame: At Day 43
At Day 43
Percentage of participants with seroresponse to anti-HAV for the 3 pooled lots of VNS vaccine groups compared with the 2 pooled lots of VV groups in HAV subset
Time Frame: At Day 43

Seroresponse is defined as post-vaccination (Day 43) anti-HAV antibody concentration >= cut-off value among participants who were seronegative (antibody concentration < cut-off value) before vaccination.

The assay cut-off values for anti-HAV antibodies will be defined by the laboratory before the analysis.
At Day 43
Anti-S. pneumoniae serotype specific Polysaccharide IgG antibody concentrations for the 3 pooled lots of VNS vaccine groups compared with the 2 pooled lots of VV groups in PCV subset
Time Frame: At Day 43
S. pneumoniae polysaccharides to be tested: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F.
At Day 43
Percentage of participants in the VNS vaccine pooled group with anti-VZV gE antibody concentrations above the adaptive seroresponse threshold
Time Frame: At Day 43
The adaptive seroresponse threshold is the anti-VZV gE IgG antibody concentration for which the response rate in the VV group is 95% or higher.
At Day 43
Percentage of participants reporting each solicited administration site event
Time Frame: Day 1 (post-dose) to Day 4
Solicited administration site events include injection site redness, pain and swelling.
Day 1 (post-dose) to Day 4
Percentage of participants reporting each solicited systemic event in terms of fever
Time Frame: Day 1 (post-dose) to Day 22
Fever is defined as temperature greater than or equal to (>=)38.0 degrees Celsius (°C) by any route (the preferred location for measuring temperature is the axilla).
Day 1 (post-dose) to Day 22
Percentage of participants reporting each solicited administration site event
Time Frame: Day 1 (post-dose) to Day 43
Solicited administration site events include injection site varicella-like rash.
Day 1 (post-dose) to Day 43
Percentage of participants reporting each solicited systemic event
Time Frame: Day 1 (post-dose) to Day 43
Solicited systemic events include varicella-like rash (non-injection site) and general rash (not varicella-like).
Day 1 (post-dose) to Day 43
Percentage of participants reporting unsolicited adverse events (AEs)
Time Frame: Day 1 (post-dose) to Day 43
Unsolicited AEs include any AE reported in addition to solicited events during the study, or any "solicited" symptoms with onset outside of the specified period of follow-up for solicited symptoms, are assessed for each group after the administration of all vaccines.
Day 1 (post-dose) to Day 43

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
GlaxoSmithKline

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 10, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 25, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 17, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 12, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 12, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 18, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 29, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 27, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 213998
  • 2024-515869-33-00 (Other Identifier: EU CT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

IPD Sharing Time Frame

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

IPD Sharing Access Criteria

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings